A series of pyrrole derivatives and their preparation method and therapeutic use
US-2024327423-A1 · Oct 3, 2024 · US
Quinazoline analogs as receptor tyrosine kinase inhibitors
US2021284656A9 · US · A9
| Field | Value |
|---|---|
| Publication number | US-2021284656-A9 |
| Application number | US-201916264194-A |
| Country | US |
| Kind code | A9 |
| Filing date | Jan 31, 2019 |
| Priority date | Aug 14, 2003 |
| Publication date | Sep 16, 2021 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of treating gliomas, cancer of the ovary, bladder cancer, cancer of the esophagus, cancer of the uterus, prostate cancer, kidney cancer, skin cancer, cancer of the pancreas, leukemias, or lymphomas comprising administering a therapeutically effective amount of a compound selected from the group consisting of: 2 . The method of claim 1 , wherein the compound is: 3 . A method of inhibiting the activity of ErbB2 comprising administering a compound selected from the group consisting of: 4 . The method of claim 3 , wherein the compound is: 5 . A method of treating diseases or medical conditions mediated by type I receptor tyrosine kinases which comprises administering to a warm-blooded animal an effective amount of a compound selected from the group consisting of: 6 . The method of claim 5 , wherein the type I receptor tyrosine kinase is ErbB2. 7 . The method of claim 5 , wherein the compound is: 8 . The method of claim 6 , wherein the compound is:
Assignees
Inventors
Classifications
Organic additives · CPC title
Antineoplastic agents · CPC title
Nitrogen atoms · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2021284656A9 cover?
- The invention includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
- Who is the assignee on this patent?
- Array Biopharma Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D498/10. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Sep 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (A9). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).